Mysterious Buyer in First Bank Spurs Nigerian Regulator's Query
Barbican Capital Ltd., managed by Oyeleye and Otudeko, and other investors sold about 25% of First HoldCo Plc, the parent of First Bank of Nigeria Ltd., on July 16, according to data provided by Nigeria's Securities and Exchange Commission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
6 minutes ago
- Entrepreneur
UAE Opens Golden Visa Path to Investors Without Sponsorship
You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media. In a significant move to attract global talent and long-term investment, the United Arab Emirates has simplified the process for investors to obtain the coveted Golden Visa—now available without the need for a local sponsor. The announcement, made by the Federal Authority for Identity, Citizenship, Customs and Port Security (ICP), outlines a streamlined, eight-step application procedure aimed at facilitating business and economic growth. Previously, the 10-year Golden Residency Visa often required backing by a company or government entity. Under the new system, investors and business owners can apply independently, making the UAE even more attractive to international entrepreneurs and high-net-worth individuals seeking stability, access to regional markets, and tax advantages. Applicants must provide proof of a minimum AED 2 million investment in the country through real estate, business capital, or public projects. They are also required to submit supporting documents, such as audited financial statements and proof of income, alongside a valid passport. The revised pathway is part of the UAE's broader efforts to diversify its economy and strengthen its position as a global business hub. By removing barriers to long-term residency, authorities hope to retain top talent, boost local investment, and encourage innovation in sectors like technology, finance, and renewable energy. Since its inception in 2019, the Golden Visa has been a cornerstone of the UAE's residency reform strategy. Expanding eligibility and easing procedural constraints signals a deeper commitment to economic openness and global competitiveness. Investors can initiate their application online through the ICP portal, with most approvals expected within a few weeks, pending background and security checks. With this policy shift, the UAE reinforces its image not just as a transit economy—but as a destination for long-term investment and high-impact entrepreneurship.
Bloomberg
7 minutes ago
- Bloomberg
Valterra Platinum Cuts First-Half Dividend 79% as Profit Slumps
Valterra Platinum Ltd. said first-half profit fell 91%, after flooding at a key mine cut production and the company incurred costs during its recent spinoff from Anglo American Plc. The Johannesburg-listed miner also slashed its interim dividend to 2 rand per share, a drop of 79% compared with a year earlier, according to results released on Monday. Valterra completed its separation from Anglo at the start of June.
Yahoo
35 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
